| 2024 GUIDANCE | |||
| Earnings (per diluted share) | Previous | Revised | Change at M.P. |
| Net earnings attributable to common stockholders | $3.20 to $3.45 | $3.15 to $3.35 | (2.3) % |
| Core FFO attributable to common stockholders/unitholders* | $5.42 to $5.56 | $5.37 to $5.47 | (1.3) % |
| Core FFO attributable to common stockholders/unitholders, excluding Net Promote Income (Expense)*1 | $5.50 to $5.64 | $5.45 to $5.55 | (1.3) % |
Why ProMIS Neurosciences Stock Surged Today
ProMIS Neurosciences Inc. (NASDAQ: PMN) shares skyrocketed Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's disease (AD), PMN310, and additional studies that further characterize a computationally-derived AD vaccine <
